Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf
التنسيق: Artigo
اللغة:Inglês
منشور في: Medical Journals Sweden 2022-04-01
سلاسل:Acta Dermato-Venereologica
الموضوعات:
Locally advanced basal cell carcinoma
Vismodegib
Effectiveness
Safety
Non-interventional study
German ADOReg skin cancer registry
الوصول للمادة أونلاين:https://medicaljournalssweden.se/actadv/article/view/293
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة